A breakdown of the latest mutual funds holding Bluebird bio Inc (BLUE)

Stocks of Bluebird bio Inc (NASDAQ:BLUE) traded higher last session on Wall Street, down -5.36% to $1.06.

BLUE stock price is now -11.15% away from the 50-day moving average and -54.50% away from the 200-day moving average. The market capitalization of the company currently stands at $204.30M.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Sponsored

#####

On December 08, 2023, Morgan Stanley Upgraded its previous ‘Underweight’ rating to ‘Equal-Weight’ on the stock increasing its target price from $3 to quote $7, while ‘Cantor Fitzgerald’ rates the stock as ‘Neutral’

In other news, Obenshain Andrew, President and CEO sold 6,095 shares of the company’s stock on Mar 04 ’24. The stock was sold for $9,311 at an average price of $1.53. Upon completion of the transaction, the President and CEO now directly owns 279,998 shares in the company, valued at $0.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, Klima Thomas J sold 4,573 shares of the business’s stock. A total of $6,986 was realized by selling the stock at an average price of $1.53. This leaves the insider owning 124,840 shares of the company worth $0.13 million. A total of 1.51% of the company’s stock is owned by insiders.

During the past 12 months, Bluebird bio Inc has had a low of $0.85 and a high of $5.53. As of last week, the company has a debt-to-equity ratio of 1.36, a current ratio of 1.55, and a quick ratio of 1.42.

According to the Biotechnology Company, earnings per share came in at 0.38, beating analysts’ expectations of -0.44 by 0.82. This compares to -$0.94 EPS in the same period last year. The net profit margin was -419.62% and return on equity was -47.81% for BLUE. The company reported revenue of $12.39 million for the quarter, compared to $71000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17353.52 percent. For the current quarter, analysts expect BLUE to generate $10.13M in revenue.

#####

#####

Related Posts